Toward a multifactorial model of Alzheimer disease

Neurobiology of Aging

Volumn 33, Issue 10, 2012, Pages 2262-2271

  Storandt, Martha ^a,b   Head, Denise ^a   Fagan, Anne M ^b   Holtzman, David M ^b   Morris, John C ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid plaque; Amyloid Tau; APOE; Biomarkers; Brain volumetry; Cerebrospinal fluid; Memory; PIB; Preclinical Alzheimer disease

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; PITTSBURGH COMPOUND B; TAU PROTEIN;

ADULT; AGE; AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; ARTICLE; BRAIN REGION; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DISEASE ASSOCIATION; GENE; GENOTYPE; HUMAN; LONGITUDINAL STUDY; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; PSYCHOMETRY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BRAIN; COGNITION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, NEUROLOGICAL; ORGAN SIZE; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; THIAZOLES;

EID: 84864324855     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.11.029     Document Type: Article

References (42)

1. Apostolova L.G., Hwang K.S., Andrawis J.P., Green A.E., Babakchanian S., Morra J.H., Cummings J.L., Toga A.W., Trojanowski J.Q., Shaw L.M., Jack C.R., Petersen R.C., Aisen P.S., Jagust W.J., Koeppe R.A., Mathis C.A., Weiner M.W., Thompson P.M. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol. Aging 2010, 31:1452-1462. Alzheimer's Disease Neuroimaging Initiative.
2. Armitage S.G. An analysis of certain psychological tests used for the evaluation of brain injury. Psychol. Monogr 1945, 60:1-48.
3. Becker J.A., Hedden T., Carmasin J., Maye J., Rentz D.M., Putcha D., Fischl B., Greve D.N., Marshall G.A., Salloway S., Marks D., Buckner R.L., Sperling R.A., Johnson K.A. Amyloid-β associated cortical thinning in clinically normal elderly. Ann. Neurol 2011, 69:1032-1042.
4. Berg L., McKeel D.W., Miller J.P., Storandt M., Rubin E.H., Morris J.C., Baty J., Coats M., Norton J., Goate A.M., Price J.L., Gearing M., Mirra S.S., Saunders A.M. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol 1998, 55:326-335.
5. Chételat G., Villemagne V.L., Pike K.E., Baron J.C., Bourgeat P., Jones G., Faux N.G., Ellis K.A., Salvado O., Szoeke C., Martins R.N., Ames D., Masters C.L., Rowe C.C. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010, 133:3349-3358. Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group, Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group.
6. Cohen J., Cohen P., West S.G., Aiken L.S. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences 2002, Lawrence Erlbaum Associates, Mahway, NJ. 3rd.
7. Desikan R.S., McEvoy L.K., Thompson W.K., Holland D., Roddey J.C., Blennow K., Aisen P.S., Brewer J.B., Hyman B.T., Dale A.M. Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann. Neurol 2011, 70:657-661. Alzheimer's Disease Neuroimaging Initiative.
8. Desikan R.S., Ségonne F., Fischl B., Quinn B.T., Dickerson B.C., Blacker D., Buckner R.L., Dale A.M., Maguire R.P., Hyman B.T., Albert M.S., Killiany R.J. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006, 31:968-980.
9. Fagan A.M., Head D., Shah A.R., Marcus D., Mintun M., Morris J.C., Holtzman D.M. Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly. Ann. Neurol 2009, 65:176-183.
10. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol 2006, 59:512-519.
11. 181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO. Mol. Med 2009, 1:371-380.
12. Fennema-Notestine C., Gamst A.C., Quinn B.T., Pacheco J., Jernigan T.L., Thal L., Buckner R., Killiany R., Blacker D., Dale A.M., Fischl B., Dickerson B., Gollub R.L. Feasibility of multi-site clinical structural neuroimaging studies of aging using legacy data. Neuroinformatics 2007, 5:235-245.
13. Fischl B., Salat D.H., Busa E., Albert M., Dieterich M., Haselgrove C., van der Kouwe A., Killiany R., Kennedy D., Klaveness S., Montillo A., Makris N., Rosen B., Dale A.M. Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355.
14. Goodglass H., Kaplan E. The Assessment of Aphasia and Related Disorders 1983, Lee & Febiger, Philadelphia, PA. 2nd.
15. Grober E., Buschke H., Crystal H., Bang S., Dresner R. Screening for dementia by memory testing. Neurology 1988, 3:900-903.
16. Holtzman D.M., Morris J.C., Goate A.M. Alzheimer's disease: The challenge of the second century. Sci. Transl. Med. 2011, 3(77):77sr1.
17. Hong S., Quintero-Monzon O., Ostaszewski B.L., Podlisny D.R., Cavanaugh W.T., Yang T., Holtzman D.M., Cirrito J.R., Selkoe D.J. Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. J. Neurosci 2011, 31:15861-15869.
18. Hyman B.T. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch. Neurol 2011, 68:1062-1064.
19. Jack C.R., Lowe V.J., Wegland S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M., Petersen R.C. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365. The Alzheimer's Disease Neuroimaging Initiative.
20. Jovicich J., Czanner S., Han X., Salat D., van der Kouwe A., Quinn B., Pacheco J., Albert M., Killiany R., Blacker D., Maguire P., Rosas D., Makris N., Gollub R., Dale A., Dickerson B.C., Fischl B. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. Neuroimage 2009, 46:177-192.
21. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Lεngström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 2004, 55:306-319.
22. Kronmal R.A. Spurious correlations and the fallacy of the ratio standard revisited. J. R. Stat. Soc'Y (Series A) 1993, 156:379-392.
23. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab 1996, 16:834-840.
24. McEvoy L.K., Fennema-Notestine C., Roddey J.C., Hagler D.J., Holland D., Karow D.S., Pung C.J., Brewer J.B., Dale A.M. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 2009, 251:195-205. Alzheimer's Disease Neuroimaging Initiative.
25. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
26. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., Koeppe R.A., Mathis C.A., Weiner M.W., Jagust W.J. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323. Alzheimer's Disease Neuroimaging Initiative.
27. Morris J.C. The Clinical Dementia Rating (CDR)-current version and scoring rules. Neurology 1993, 43:2412-2414.
28. Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., Mintun M.A. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol 2010, 67:122-131.
29. Oh H., Mormino E.C., Madison C., Hayenga A., Smiljic A., Jagust W.J. β-amyloid affects frontal and posterior brain networks in normal aging. Neuroimage 2011, 54:1887-1895.
30. Pearson K. Mathematical contributions to the theory of evolution-on a form of spurious correlation which may arise when indices are used in the measurements of organs. Proc R. Soc. London 1897, 60:489-497.
31. Pimplikar S.W. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int. J. Biochem. Cell Biol 2009, 41:1261-1268.
32. Price J.L., Ko A.I., Wade M.J., Tsou S.K., McKeel D.W., Morris J.C. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol 2001, 58:1395-1402.
33. Price J.L., McKeel D.W., Buckles V.D., Roe C.M., Xiong C., Grundman M., Hansen L.A., Petersen R.C., Parisi J.E., Dickson D.W., Smith C.D., Davis D.G., Schmitt F.A., Markesbery W.R., Kaye J., Kurlan R., Hulette C., Kurland B.F., Higdon R., Kukull W., Morris J.C. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 2009, 30:1026-1036.
34. Raz N., Rodrigue K.M. Differential aging of the brain: Patterns, cognitive correlates and modifiers. Neurosci. Biohav. Rev 2006, 30:730-748.
35. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V.L. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31:1275-1283.
36. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann. Neurol 2009, 65:403-413. Alzheimer's Disease Neuroimaging Initiative.
37. Small S., Duff K. Linking Aβ and tau in late-onset Alzheimer's disease: A dual pathway hypothesis. Neuron 2008, 600:534-542.
38. Storandt M., Mintun M.A., Head D., Morris J.C. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch. Neurol 2009, 66:1476-1481.
39. Sunderland T., Mirza N., Putnam K.T., Linker G., Bhupali D., Durham R., Soares H., Kimmel L., Friedman D., Bergeson J., Csako G., Levy J.A., Bartko J.J., Cohen R.M. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE epsilon4 allele. Biol. Psychiatry 2004, 56:670-676.
40. Tolboom N., van der Flier W.M., Yaqub M., Boellaard R., Verwey N.A., Blankenstein M.A., Windhorst A.D., Scheltens P., Lammertsma A.A., van Berckel B.N. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J. Nucl. Med 2009, 50:1464-1470.
41. Tosun D., Schuff N., Truran-Sacrey D., Shaw L.M., Trojanowski J.Q., Aisen P., Peterson R., Weiner M.W. Relations between brain tissue loss, CSF biomarkers, and the APOE genetic profile: A longitudinal MRI study. Neurobiol. Aging 2010, 31:1340-1354. Alzheimer's Disease Neuroimaging Initiative.
42. Vemuri P., Wiste H.J., Weigand S.D., Knopman D.S., Shaw L.M., Trojanowski J.Q., Aisen P.S., Weiner M., Petersen R.C., Jack C.R. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann. Neurol 2010, 67:308-316. Alzheimer's Disease Neuroimaging Initiative.